Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diatos SA's Belgium subsidiary Diatos NV has received E650,000 in funding to support its oncology research program through a grant from the Flemish Institute for Science and Technology, a Flemish government institution.
Subscribe to our email newsletter
Diatos NV focuses its research on anticancer prodrugs, based on one of Diatos’s two core technology platforms, known as tumor-selective prodrug technology (TSP). The funding of E650,000 over the next two years will be applied to extend the TSP concept to the development of cytokines prodrugs with anti-tumor activity.
Using Diatos’s proprietary TSP technology allows the targeted delivery of prodrugs to tumor sites, where a linker peptide is cleaved off and the active compound is released locally. It has several advantages over conventional chemotherapy, according to the company, including higher doses, reduced toxicity and increased efficacy.
“We are very pleased with this financial boost in our quest to develop safer and better cancer medicines,” said Dr Henk Snyman, managing director of Diatos NV. “The Flemish Institute for Science and Technology (IWT) grant and support further strengthens our ties with Flanders and our activities and profile in Belgium.”